<DOC>
	<DOCNO>NCT01610869</DOCNO>
	<brief_summary>The primary objective explore efficacy safety oral combination BIBF 1120 ( inhibitor angiogenic signal ) metronomic cyclophosphamide patient multiply-relapsed advanced ovarian cancer , complete minimum two line previous chemotherapy reason suitable 'standard ' intravenous chemotherapy treatment .</brief_summary>
	<brief_title>Low Dose Cyclophosphamide +/ -- Nintedanib Advanced Ovarian Cancer</brief_title>
	<detailed_description>A randomised placebo control double blind multi-centre phase II trial : BIBF 1120 200mg bd plus 100mg daily oral cyclophosphamide ( experimental arm ) oral cyclophosphamide 100mg daily plus placebo ( control arm ) . Patients receive oral BIBF 1120 cyclophosphamide cyclophosphamide placebo continuously disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Female subject , â‰¥18 year , histologically proven recurrent advance epithelial ovarian , fallopian tube primary peritoneal carcinoma Have either undergone hysterectomy bilateral oophorectomy/salpingectomy and/or postmenopausal 24 consecutive month ( i.e . menses time precede 24 consecutive month without alternative medical cause ) Performance status 02 Adequate organ function Life expectancy &gt; 6 week Has receive 2 line chemotherapy ovarian cancer patient platinum resistant platinum intolerant suitable standard intravenous chemotherapy No previous oral cyclophosphamide , nintedanib , tyrosine kinase inhibitor cediranib patient receive antiVEGF therapy bevacizumab stratify Measurable lesion accord RECIST 1.1 criterion serum CA125 level evaluation GCIG CA125 criterion welcome prerequisite inclusion response assess evaluable disease Able give write informed consent complete QoL Exclusion Criteria Carcinosarcoma malignant tumour nonepithelial origin ( e.g . germ cell tumour , sex cordstromal tumour ) ovary , fallopian tube peritoneum Clinically relevant nonhealing wound , ulcer ( intestinal tract , skin ) bone fracture Symptoms sign gastrointestinal obstruction require parenteral nutrition hydration GI disorder abnormality would interfere drug absorption inability take oral medication Active brain metastasis ( i.e . symptom deteriorate , change condition &lt; 4 week ) leptomeningeal disease . Trial entry allow brain metastasis stable ( asymptomatic condition stable &gt; 4 week ) . Dexamethasone brain metastasis allow administer stable dose &gt; 4 week randomisation ( &lt; 4 week patient eligible ) Clinically relevant therapyrelated toxicity previous chemotherapy radiotherapy History major thromboembolic event within last 6 month , pulmonary embolism proximal deep vein thrombosis , unless stable therapeutic anticoagulation ( &gt; 3 month warfarin , PT / INR need monitor regularly per table 8.1 protocol ) Known inherit acquire bleed disorder Significant cardiovascular disease , include uncontrolled hypertension , clinically relevant cardiac arrhythmia , unstable angina myocardial infarction within past 6 month , congestive heart failure &gt; NYHA II , severe peripheral vascular disease , significantly relevant pericardial effusion History cerebral vascular accident , transient ischemic attack subarachnoid hemorrhage within past 6 month Radiographic evidence cavitating necrotic tumour invasion adjacent major blood vessel Laboratory value indicate increase risk adverse event : 1. calculate GFR &lt; 45 ml/min . Sites use calculation method accord local practice . 2. absolute neutrophil count ( ANC ) &lt; 1.5x109/L 3. platelet &lt; 100 x109/L 4. haemoglobin &lt; 90 g/L 5. proteinuria CTCAE 2 great 6. total bilirubin &gt; x 2 ULN 7 . ALT and/or AST &gt; 1.5 x ULN 8. unless liver metastasis present ALT AST &gt; 2.5 ULN 9. International normalize ratio ( INR ) &gt; 2 activate partial thromboplastin time ( APTT ) &gt; 1.5 x ULN absence therapeutic anticoagulation . INR &gt; 4 APTT &gt; 2.5 x ULN presence therapeutic anticoagulation Serious infection particular require systemic antibiotic ( antimicrobial , antifungal antiviral therapy ) , include hepatitis B and/or C infection , HIV infection Poorly control diabetes mellitus patient sulphonylureatype hypoglycaemics ( e.g . gliclazide ) main diabetic control ( contraindicate cyclophosphamide ) Previous breast cancer patient permit diagnosis chemotherapy treatment &gt; 5 year previously evidence metastatic breast cancer trial entry ( Please contact UCL CTC / CI patient still hormone treatment breast cancer ) . Other malignancy diagnose within past 5 year . In exception rule , follow malignancy may include : 1. nonmelanoma skin cancer ( adequately treat ) 2. cervical carcinoma situ ( adequately treat ) 3. prior synchronous endometrial cancer ( adequately treat ) , provide follow criterion meet : G1 G2 , LVSI FIGO ( 2010 ) stage IA Serious illness concomitant nononcological disease neurologic , psychiatric infectious disease laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule e.g . active alcohol drug abuse Any contraindication therapy cyclophosphamide , e.g . history severe hypersensitivity reaction list excipients cyclophosphamide treatment investigational drug Patients commence trial treatment within 6 week major surgical procedure Participation another clinical trial test drug within past four week start therapy concomitantly trial Chemotherapy , include immunotherapy monoclonal antibody treatment ( VEGF ) within 4 week start study treatment Hormone treatment ovarian cancer within 2 week start study treatment ( ongoing HRT allowable ) Any previous tyrosine kinase inhibitor treatment predominantly antiangiogenic action Radiotherapy within 3 month allow except give symptom control &gt; 28d previously . All patient receive radiotherapy require evidence recurrent ovarian cancer outside irradiated field either image via rise CA125 Hypersensitivity nintedanib , peanut soya , excipients nintedanib</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Recurrence</keyword>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Ovarian Diseases</keyword>
	<keyword>Fallopian Tube Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Neoplasms site</keyword>
</DOC>